A leap towards personalised therapy of acute lung injury
- PMID: 36522140
- DOI: 10.1183/13993003.01808-2022
A leap towards personalised therapy of acute lung injury
Conflict of interest statement
Conflict of interest: M. Witzenrath reports grants from Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, Deutsche Gesellschaft für Pneumologie, European Respiratory Society, Marie Curie Foundation, Else Kröner Fresenius Stiftung, Capnetz Stiftung, International Max Planck Research School, Actelion, Bayer Health Care, Biotest and Boehringer Ingelheim; consulting fees from Noxxon, Pantherna, Vaxxilon, Aptarion, GlaxoSmithKline, Sinoxa and Biotest; lecture honoraria from AstraZeneca, Berlin Chemie, Chiesi, Novartis, Teva, Actelion, Boehringer Ingelheim, GlaxoSmithKline, Biotest and Bayer Health Care; and has patents EPO 12181535.1 (IL-27 for modulation of immune response in acute lung injury), WO/2010/094491 (Means for inhibiting the expression of Ang-2), DE 102020116249.9 (Camostat/Niclosamide cotreatment in SARS-CoV-2 infected human lung cells) and PCT/EP2021/075627 (New medical use of cystic fibrosis transmembrane conductance regulator (CFTR) modulators) issued; outside the submitted work. T. Welte reports grants from German Ministry of Research and Education.
Comment on
-
Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients.Eur Respir J. 2022 Dec 15;60(6):2200780. doi: 10.1183/13993003.00780-2022. Print 2022 Dec. Eur Respir J. 2022. PMID: 35896211 Free PMC article. Clinical Trial.
-
A biomarker assay to risk-stratify patients with symptoms of respiratory tract infection.Eur Respir J. 2022 Dec 15;60(6):2200459. doi: 10.1183/13993003.00459-2022. Print 2022 Dec. Eur Respir J. 2022. PMID: 36104292 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical